Novartis AG
NVS Real Time Price USD$NVS is featured in our Shelley Moore Capito strategy.
All StrategiesRecent trades of NVS by members of U.S. Congress
---
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in NVS holdings by institutional investors
Quarterly net insider trading by NVS's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More about Alpha -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More about Annual Standard Deviation -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More about Annual Volatility -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More about Beta -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More about CAGR -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More about Information Ratio -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More about Max Drawdown -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More about Sharpe Ratio -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More about Treynor Ratio -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$40,000 Feb 04, 2003 Issue: Agriculture
NVS Estimated quarterly lobbying spending
NVS Revenue by Segment or Geography
New NVS patent grants
-
Patent Title: Soft tip cannula Sep. 12, 2017
-
Patent Title: Tissue-sensing vitrectomy surgical systems and methods Sep. 12, 2017
-
Patent Title: Methods of treatment by administering an anti-baffr antibody therapeutic formulation Sep. 05, 2017
-
Patent Title: Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension Sep. 05, 2017
-
Patent Title: Circulation of components during microfluidization and/or homogenization of emulsions Sep. 05, 2017
-
Patent Title: Ophthalmic device having therapeutic agent delivery capability and method of forming same Sep. 05, 2017
-
Patent Title: Systems and methods for ocular surgery Sep. 05, 2017
-
Patent Title: Aspiration device with vacuum limiter Sep. 05, 2017
-
Patent Title: Peptides and compositions for treatment of joint damage Aug. 29, 2017
-
Patent Title: Aerosolization apparatus for inhalation profile-independent drug delivery Aug. 29, 2017
-
Patent Title: Methods of treating ankylosing spondylitis using il-17 antagonists Aug. 29, 2017
-
Patent Title: Quality control methods for oil-in-water emulsions containing squalene Aug. 29, 2017
-
Patent Title: Respirable agglomerates of porous carrier particles and micronized drug Aug. 29, 2017
-
Patent Title: Capsular ring with improved fixation and centering Aug. 29, 2017
-
Patent Title: Silicone hydrogel lens with a crosslinked hydrophilic coating Aug. 22, 2017
-
Patent Title: Nucleic acids and proteins from streptococcus groups a and b Aug. 22, 2017
-
Patent Title: Lens mold carrier Aug. 15, 2017
-
Patent Title: Devices, systems, and methods for tip vacuum control during aspiration Aug. 15, 2017
-
Patent Title: Burst mode vitrectomy system Aug. 15, 2017
-
Patent Title: Variable stiffness cannula and methods for a surgical system Aug. 15, 2017
-
Patent Title: Movable wide-angle ophthalmic surgical system Aug. 08, 2017
-
Patent Title: Laser apparatus and method for laser processing a target material Aug. 08, 2017
-
Patent Title: Polymerizable polysiloxanes with hydrophilic substituents Aug. 01, 2017
-
Patent Title: Poly(oxazoline-co-ethyleneimine)-epichlorohydrin copolymers and uses thereof Aug. 01, 2017
-
Patent Title: Isoxazoline hydroxamic acid derivatives as lpxc inhibitors Aug. 01, 2017
-
Patent Title: Methods of treating psoriasis using il-17 antibody Aug. 01, 2017
-
Patent Title: Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases Aug. 01, 2017
-
Patent Title: Vitreoretinal membrane characterization using optical coherence tomography Aug. 01, 2017
-
Patent Title: Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease Jul. 25, 2017
-
Patent Title: Heterocyclic compounds and methods of their use Jul. 25, 2017
-
Patent Title: Surgical utility connector Jul. 25, 2017
-
Patent Title: Optical instrument alignment system Jul. 25, 2017
-
Patent Title: Heterocyclic compounds and methods for their use Jul. 18, 2017
-
Patent Title: Silicone hydrogel lens with a crosslinked hydrophilic coating Jul. 18, 2017
-
Patent Title: Apparatus for monitoring one or more surgical parameters of the eye Jul. 18, 2017
-
Patent Title: Apparatus for optical coherence tomography of an eye and method for optical coherence tomography of an eye Jul. 11, 2017
-
Patent Title: Ophthalmic lubrication system and associated apparatus, systems, and methods Jul. 11, 2017
-
Patent Title: Arranging interaction and back pressure chambers for microfluidization Jul. 11, 2017
-
Patent Title: Compounds and compositions for the treatment of parasitic diseases Jul. 11, 2017
-
Patent Title: Pharmaceutical combinations of a cdk4/6 inhibitor and a b-raf inhibitor Jul. 11, 2017
-
Patent Title: Biaryl amide compounds as kinase inhibitors Jul. 04, 2017
-
Patent Title: Double-acting vitreous probe with contoured port Jul. 04, 2017
-
Patent Title: Systems and methods for ocular surgery Jul. 04, 2017
-
Patent Title: Ophthalmic visualization devices, systems, and methods Jul. 04, 2017
-
Patent Title: Silent fc variants of anti-cd40 antibodies Jun. 27, 2017
-
Patent Title: Chemokine receptor binding polypeptides Jun. 27, 2017
-
Patent Title: Compounds and compositions for inducing chondrogenesis Jun. 27, 2017
-
Patent Title: 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh Jun. 27, 2017
-
Patent Title: Hydrophilized carbosiloxane vinylic monomers Jun. 20, 2017
-
Patent Title: Antibody molecules to pd-1 and uses thereof Jun. 20, 2017
Federal grants, loans, and purchases
Estimated quarterly amount awarded to NVS from public contracts
Recent insights relating to NVS
Recent picks made for NVS stock on CNBC
ETFs with the largest estimated holdings in NVS
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $NVS stock a Buy, Sell, or Hold?
- What is the price target for $NVS stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $NVS stock?
- Who owns the most shares of $NVS stock?
- What funds own $NVS stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view NVS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
We estimate that -- received a compensation of -- in --, making them the highest paid executive at NVS, per a recent SEC DEF 14A filing.
|
Name
|
Role
|
Salary
|
Bonus
|
Stock/Option Awards
|
Total Compensation
|
|---|